Cowden syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 8: | Line 8: | ||
==Medical Therapy== | ==Medical Therapy== | ||
*[[Pharmacological|Pharmacologic]] medical [[therapy]] is recommended among patients with [[cutaneous]] manifestations in [[cowden syndrome]] patients. | *[[Pharmacological|Pharmacologic]] medical [[therapy]] is recommended among patients with [[cutaneous]] manifestations in [[cowden syndrome]] patients. | ||
**Preferred regimen (1): [[Acitretin]] 30 mg/day for [[cutaneous]] manifestations. | **Preferred regimen (1): [[Acitretin]] 30 mg/day for [[cutaneous]] manifestations.<ref name="pmid21882176">{{cite journal |vauthors=Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, Novotny PJ, Alberts SR, Limburg PJ, Pittelkow MR |title=Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251) |journal=Cancer |volume=118 |issue=8 |pages=2128–37 |date=April 2012 |pmid=21882176 |pmc=3365547 |doi=10.1002/cncr.26374 |url=}}</ref> | ||
***Side effects: | ***Side effects: | ||
****[[Teratogenicity]] | ****[[Teratogenicity]] | ||
Revision as of 12:57, 19 March 2019
|
Cowden syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cowden syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Cowden syndrome medical therapy |
|
Risk calculators and risk factors for Cowden syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
Due to different phenotypes cowden syndrome is likely to be an underdiagnosed condition. Pharmacologic medical therapy is recommended among patients with cutaneous manifestations in cowden syndrome.
Medical Therapy
- Pharmacologic medical therapy is recommended among patients with cutaneous manifestations in cowden syndrome patients.
- Screening for multiple cancers should be effectively done in the patients with cowden syndrome.
References
- ↑ Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, Novotny PJ, Alberts SR, Limburg PJ, Pittelkow MR (April 2012). "Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)". Cancer. 118 (8): 2128–37. doi:10.1002/cncr.26374. PMC 3365547. PMID 21882176.